The Importance of Time to Prostate-Specific Antigen (PSA) Nadir after Primary Androgen Deprivation Therapy in Hormone-Naïve Prostate Cancer Patients
Prostate-specific antigen (PSA) is currently the most useful biomarker for detection of prostate cancer (PCa). The ability to measure serum PSA levels has affected all aspects of PCa management over the past two decades. The standard initial systemic therapy for advanced PCa is androgen-deprivation...
Main Authors: | Takeshi Sasaki, Yoshiki Sugimura |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-12-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/7/12/565 |
Similar Items
-
Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation
by: Fady B. Geara, et al.
Published: (2017-09-01) -
Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy
by: Jeremy YC Teoh, et al.
Published: (2017-01-01) -
Predictors of survival outcomes in native sub Saharan black men newly diagnosed with metastatic prostate cancer
by: Jibril Oyekunle Bello
Published: (2017-05-01) -
Relationship between two year PSA nadir and biochemical recurrence in prostate cancer patients treated with iodine-125 brachytherapy
by: Carlos Antônio da Silva Franca, et al.
Published: (2014-04-01) -
Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer
by: Hideyasu Tsumura, et al.
Published: (2016-04-01)